"In this study, we demonstrated that ibrutinib treatment enhances the feasibility of generating CAR T cells from CLL patients."
"Given that 90% or more of patients with high-risk disease have an initial response to ibrutinib and typically remain on ibrutinib therapy for over 1 year, this time window may provide an optimal opportunity to collect T cells and to subsequently administer a potentially curative T cell–based therapy that would allow for cessation of drug treatment. "
"In summary, we have shown that long-term ibrutinib treatment reverses the dysfunction of T cells in CLL, which has implications for both the mechanism of action of ibrutinib and the potential use of T-cell therapies. The enhanced ex vivo proliferative capacity of CAR-redirected lymphocytes is a strong predictive indicator of their ability to engraft in vivo and mediate antitumor responses. This increased therapeutic potential is further supported by the synergistic effect of CAR T cells and ibrutinib in resistant models of acute and chronic leukemia. These data suggest that clinical trials with ibrutinib lead-in and then continued treatment could enhance the efficacy and engraftment of adoptively transferred T cells, including CAR T cells."
Irina, CLL Norway